OH SB274

Designates the first full week of May as "Tardive Dyskinesia Awareness Week" in Ohio to increase public awareness of the condition.

Identifies tardive dyskinesia as a movement disorder characterized by involuntary and uncontrolled movements of muscles in the face, trunk, and extremities that can develop months, years, or decades after starting dopamine receptor blocking agent (DRBA) medications.

Notes that over 600,000 Americans suffer from tardive dyskinesia, with an estimated one in four patients receiving long-term antipsychotic treatment experiencing the condition, which is often permanent once developed.

Acknowledges recent scientific breakthroughs including two new FDA-approved treatments for tardive dyskinesia and the American Psychiatric Association's recommendation for regular screening in patients taking DRBA medications.

Finds that tardive dyskinesia is frequently unrecognized and patients are commonly misdiagnosed, making public awareness efforts necessary.